Financial Performance - The company's operating revenue for 2018 was ¥1,163,433,590.29, representing a 21.42% increase compared to ¥958,150,476.04 in 2017[21]. - The net profit attributable to shareholders for 2018 was ¥194,724,797.03, which is a 9.67% increase from ¥177,550,392.49 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥193,111,290.53, up 15.68% from ¥166,937,949.10 in 2017[21]. - The total assets at the end of 2018 were ¥2,196,483,843.13, a 22.75% increase from ¥1,789,407,728.19 at the end of 2017[21]. - The net assets attributable to shareholders increased by 19.14% to ¥1,116,216,860.63 from ¥936,873,593.32 in 2017[21]. - The basic earnings per share for 2018 were ¥0.88, an increase of 8.64% compared to ¥0.81 in 2017[21]. - The diluted earnings per share also rose to ¥0.88 from ¥0.81 in the previous year, reflecting an 8.64% increase[21]. - The weighted average return on equity for 2018 was 18.88%, down from 21.13% in 2017, indicating a decrease of 2.25%[21]. - The total operating revenue for 2018 was ¥1,163,433,590.29, representing a year-on-year increase of 21.42% compared to ¥958,150,476.04 in 2017[49]. - The revenue from active pharmaceutical ingredients (APIs) was ¥489,503,703.31, accounting for 42.07% of total revenue, with a slight increase of 0.86% from the previous year[49]. - The revenue from intermediates reached ¥665,150,924.66, which is 57.17% of total revenue, showing a significant growth of 40.67% year-on-year[49]. - Domestic sales amounted to ¥749,652,150.93, representing 64.43% of total sales, with a year-on-year increase of 17.62%[49]. - International sales were ¥413,781,439.36, making up 35.57% of total sales, with a notable increase of 28.98% compared to the previous year[49]. - The gross profit margin for the pharmaceutical manufacturing industry was 37.25%, which is a decrease of 0.95% from the previous year[51]. Research and Development - The company focuses on two main product lines in the antibiotic sector, emphasizing the development of sterile raw materials and formulations[6]. - The company plans to continue investing in R&D to ensure sustainable product development and market competitiveness[7]. - The company emphasizes the importance of market research to guide its drug development efforts[8]. - The company has established a high-tech R&D center to support innovative product development[7]. - The company’s R&D expenses increased by approximately $0.65 million, a year-on-year increase of 222.7%, indicating a focus on advancing formulation research into clinical stages[33]. - The R&D team consists of 206 members, accounting for approximately 14.58% of the total workforce, with a strong emphasis on innovation and quality research[36]. - The company plans to accelerate the R&D of new products, specifically targeting the development of new formulations and expanding the product line for Penicillin, aiming to obtain one formulation product approval within the year[88]. Environmental Commitment - The company is committed to environmental protection and has increased investment in pollution control measures[7]. - The company has maintained compliance with environmental discharge standards, with COD emissions at 72.4 mg/l, below the limit of 120 mg/l[125]. - The company has reported a significant focus on environmental protection, with no major pollution incidents or complaints during the reporting period[127]. - The company upgraded its wastewater treatment facilities, completing the second phase of upgrades to enhance wastewater recycling and utilization[127]. - The company has installed gas absorption devices in all production workshops to control emissions effectively[127]. - The company has a total of 21 environmental protection personnel, with 5 holding detection qualifications, ensuring compliance with national emission standards[130]. - The company has implemented a closed-loop system for waste gas management, significantly reducing unorganized emissions[127]. - The company has introduced advanced recycling devices to enhance the recovery and utilization of industrial solid waste[127]. - The company has established an emergency response plan for environmental incidents, filed with the local environmental protection bureau[129]. - All construction projects have passed environmental impact assessments and obtained necessary permits[128]. - The company is committed to optimizing green production processes to minimize pollutant generation[127]. - The company has made substantial investments in advanced equipment and environmentally friendly technologies to improve overall environmental performance[127]. Shareholder Returns and Capital Management - The company reported a cash dividend of 2 RMB per 10 shares and a stock bonus of 2 shares per 10 shares, with no capital reserve conversion[9]. - The company initiated a share repurchase program, acquiring 4,041,304 shares for a total amount of RMB 69,858,967.50, to enhance investor confidence[41]. - The company has completed 34.93% of its share repurchase plan with a funding limit of RMB 200 million[42]. - The company successfully issued convertible bonds with a total scale of no more than RMB 420 million, net proceeds amounting to RMB 411.98 million after deducting issuance costs[43]. - The company is committed to a shareholder return plan for the next three years (2018-2020)[45]. - The cash dividend distributed represents 24.23% of the total distributable profit of 194,724,797.03 CNY[92]. - The company has not proposed a cash dividend distribution plan for the reporting period despite positive profits available for distribution[97]. - The company’s cash dividend distribution is subject to adjustments based on changes in share capital after board approval[94]. - The company will implement a cash dividend plan if it fails to take stabilization measures, with a limit of 20% of the previous year's net profit for a single instance[99]. - The company will ensure that the repurchase does not lead to a distribution of shares that does not meet listing conditions[98]. - The company will use its own funds for share repurchase[99]. - The company will announce any share reduction plans three trading days in advance[98]. - The company will disclose the reasons for not implementing price stabilization measures if applicable[99]. Market Position and Strategy - The company has increased its foreign sales revenue proportion, which poses a risk due to potential RMB appreciation against the USD[7]. - The company faces risks related to market competition and the need to diversify its product lines to ensure future growth[6]. - The company has established a stable customer base, including well-known international clients such as Fika and Arabindo, ensuring consistent demand for its products[36]. - The company is a leading supplier of β-lactamase inhibitors globally, with a focus on the production and sales of key antibiotic raw materials[31]. - The company is actively implementing an industry chain extension strategy, focusing on the transition from non-sterile to sterile raw materials[42]. - The company plans to expand its production capacity for new enzyme inhibitors as part of its growth strategy[43]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotechnology sector[104]. - Future guidance suggests a targeted revenue growth rate of approximately 10% annually, driven by strategic initiatives and market demand[168]. Corporate Governance and Compliance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[185]. - The company maintains independence from its controlling shareholder in business, personnel, assets, organization, and finance, with a complete and independent business operation capability[186]. - The company has been actively managing its internal controls and financial activities, as evidenced by the independent opinions provided by the board of directors[191]. - The company has engaged in discussions regarding the appointment of a new financial director, indicating a focus on strengthening its financial management team[192]. - The company has approved a plan to repurchase shares, which is expected to support stock price stability and shareholder confidence[192]. - The company has reported no significant internal control deficiencies during the reporting period, indicating a strong internal control environment[196]. Employee and Management Structure - The total number of employees in the company is 1,413, with 1,002 in the parent company and 411 in major subsidiaries[179]. - The company has a professional composition of 872 production personnel, 20 sales personnel, and 147 technical personnel[179]. - The total remuneration for directors and senior management during the reporting period amounts to 742.54 million yuan[178]. - The company has established a special award system as part of its compensation policy to motivate employees[181]. - The company organized a total of 84 internal training sessions, with 3,419 participants, and 9 external training sessions with 38 participants, totaling 2,578 training hours[182].

江西富祥药业股份有限公司 2018 年第三季度报告 江西富祥药业股份有限公司 2018 年第三季度报告 公告编号：2018－087 生命 • 阳光 • 未来 1 江西富祥药业股份有限公司 2018 年第三季度报告 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人包建华、主管会计工作负责人许春霞及会计机构负责人(会计主管人员)谢海 燕声明：保证季度报告中财务报告的真实、完整。 非标准审计意见提示 □ 适用 √ 不适用 2 江西富祥药业股份有限公司 2018 年第三季度报告 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,052,228,238.96 | | 1,789,407,728.19 | 14.69% | | 归 ...

江西富祥药业股份有限公司 2018 年半年度报告 江西富祥药业股份有限公司 2018 年半年度报告 公告编号：2018－057 生命 • 阳光 • 未来 1 江西富祥药业股份有限公司 2018 年半年度报告 第一节 重要提示、目录和释义 1、公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2、公司负责人包建华、主管会计工作负责人许春霞及会计机构负责人(会计主管人员)谢 海燕声明：保证本半年度报告中财务报告的真实、准确、完整。 3、非标准审计意见提示 □ 适用 √ 不适用 4、对半年度报告涉及未来计划等前瞻性陈述的风险提示 √ 适用 □ 不适用 半年度报告涉及未来计划等前瞻性陈述，该计划不构成公司对投资者的实质承诺，投资 者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 5、公司是否需要遵守特殊行业的披露要求 是 药品生物制品业 1）、市场竞争风险 公司目前主要有两个系列产品，均属于抗菌素药物行业的子行业，公司以化学合成酶抑 制剂与碳青霉烯系列品种为主，逐步开始无菌原料药和 ...

江西富祥药业股份有限公司 2018 年第一季度报告 □ 适用 √ 不适用 江西富祥药业股份有限公司 2018 年第一季度报告 公告编号：2018－026 生命 • 阳光 • 未来 1 江西富祥药业股份有限公司 2018 年第一季度报告 第一节 重要提示 1、公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2、所有董事均已出席了审议本次季报的董事会会议。 3、公司负责人包建华、主管会计工作负责人许春霞及会计机构负责人(会计主管人员)谢 海燕声明：保证季度报告中财务报表的真实、准确、完整。 4、非标准审计意见提示 2 江西富祥药业股份有限公司 2018 年第一季度报告 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 305,123,952.76 | 230,696,463.93 | 32.26% | | 归属于上 ...

江西富祥药业股份有限公司 2017 年年度报告 江西富祥药业股份有限公司 2017 年年度报告 公告编号：2018－014 生命 • 阳光 • 未来 1 江西富祥药业股份有限公司 2017 年年度报告 第一节 重要提示、目录和释义 1、 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、 公司负责人包建华、主管会计工作负责人许春霞及会计机构负责人(会计主管人 员)谢海燕声明：保证年度报告中财务报告的真实、准确、完整。 3、 董事包建华、董事程荣武、董事许春霞、独立董事刘洪、独立董事李燕、独立董 事符念平均亲自出席了本次董事会会议。董事王莺妹、董事喻文军、董事关辉因工作原因未 能亲自出席本次董事会会议，董事王莺妹委托独立董事刘洪代为出席会议并行使表决权，董 事喻文军委托董事包建华为出席会议并行使表决权，董事关辉委托独立董事李燕代为出席会 议并行使表决权。 4、 非标准审计意见提示 □ 适用 √ 不适用 5、 内部控制重大缺陷提示 □ 适用 √ 不适用 6、 对年度报告涉及未来计划等前瞻性陈述的风险提示 1）、 ...

江西富祥药业股份有限公司 2017 年第三季度报告 江西富祥药业股份有限公司 2017 年第三季度报告 公告编号：2017－075 生命 • 阳光 • 未来 1 江西富祥药业股份有限公司 2017 年第三季度报告 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人包建华、主管会计工作负责人刘智敏及会计机构负责人(会计主管人员)谢海 燕声明：保证季度报告中财务报告的真实、完整。 2 江西富祥药业股份有限公司 2017 年第三季度报告 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,724,994,521.96 | 1,398,366,733.27 | | 23.36% | | 归属于上市公司股东的净资产 ...

江西富祥药业股份有限公司 2017 年半年度报告 江西富祥药业股份有限公司 2017 年半年度报告 公告编号：2017－048 生命 • 阳光 • 未来 1 3、非标准审计意见提示 □ 适用 √ 不适用 4、对半年度报告涉及未来计划等前瞻性陈述的风险提示 √ 适用 □ 不适用 半年度报告涉及未来计划等前瞻性陈述，该计划不构成公司对投资者的实质承诺，投资 者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 5、本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素 公司是否需要遵守特殊行业的披露要求 是 江西富祥药业股份有限公司 2017 年半年度报告 第一节 重要提示、目录和释义 1、公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2、公司负责人包建华、主管会计工作负责人刘智敏及会计机构负责人(会计主管人员) 谢 海燕声明：保证本半年度报告中财务报告的真实、准确、完整。 药品生物制品业 1）市场竞争风险 公司为抗菌素药物行业特色原料药专业企业，目前以酶抑制剂与碳青霉 ...

江西富祥药业股份有限公司 2016 年年度报告 江西富祥药业股份有限公司 2016 年年度报告 公告编号：2017－011 生命 • 阳光 • 未来 1 江西富祥药业股份有限公司 2016 年年度报告 第一节 重要提示、目录和释义 1、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人包建华、主管会计工作负责人刘智敏及会计机构负责人(会计主管人员)谢 海燕声明：保证年度报告中财务报告的真实、准确、完整。 3、董事包建华、董事程荣武、董事许春霞、独立董事刘洪、独立董事李燕、独立董事符 念平均亲自出席了本次董事会会议。董事王莺妹、董事喻文军、董事关辉因工作原因未能亲 自出席本次董事会会议，董事王莺妹委托独立董事刘洪代为出席会议并行使表决权，董事喻 文军委托董事包建华为出席会议并行使表决权，董事关辉委托独立董事李燕代为出席会议并 行使表决权。 4、非标准审计意见提示 □ 适用 √ 不适用 5、内部控制重大缺陷提示 □ 适用 √ 不适用 6、对年度报告涉及未来计划等前瞻性陈述的风险提示 公司是否需要遵守 ...

1 江西富祥药业股份有限公司 2017 年第一季度报告 第一节 重要提示 江西富祥药业股份有限公司 2017 年第一季度报告 江西富祥药业股份有限公司 2017 年第一季度报告 公告编号：2017－012 生命 • 阳光 • 未来 1、公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2、董事包建华、董事程荣武、董事许春霞、独立董事刘洪、独立董事李燕、独立董事符 念平均亲自出席了本次董事会会议。董事王莺妹、董事喻文军、董事关辉因工作原因未能亲 自出席本次董事会会议，董事王莺妹委托独立董事刘洪代为出席会议并行使表决权，董事喻 文军委托董事包建华为出席会议并行使表决权，董事关辉委托独立董事李燕代为出席会议并 行使表决权。 3、公司负责人包建华、主管会计工作负责人刘智敏及会计机构负责人(会计主管人员)谢 海燕声明：保证季度报告中财务报表的真实、准确、完整。 4、非标准审计意见提示 □ 适用 √ 不适用 2 | | | | 第一节 重要提示 2 | | --- | | 第二节 公司基本情况 4 | | 第三节 重要事 ...

江西富祥药业股份有限公司 2016 年第三季度报告 江西富祥药业股份有限公司 2016 年第三季度报告 公告编号：2016－090 生命 • 阳光 • 未来 1 江西富祥药业股份有限公司 2016 年第三季度报告 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人包建华、主管会计工作负责人刘智敏及会计机构负责人(会计主管人员)谢海 燕声明：保证季度报告中财务报告的真实、完整。 2 江西富祥药业股份有限公司 2016 年第三季度报告 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,209,149,237.31 | | 1,009,658,555.36 | 19.76% | | ...